NurExone Biologic is developing an exosome-based drug delivery platform, ExoPTEN, designed to treat acute spinal cord injuries by utilizing nanosized extracellular vesicles to transport therapeutic compounds directly to damaged neurons. This technology has demonstrated the ability to regenerate and rewire neurons in lab animals, with 75% recovering motor function and bladder control after treatment.
Funding
$839.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute spinal cord injuries (SCI) result in significant neuronal damage and limited regenerative capacity, leading to permanent motor and sensory deficits. Traditional drug delivery methods often fail to effectively target the injured spinal cord tissue due to the blood-brain barrier and other physiological challenges. This lack of targeted delivery limits the therapeutic efficacy of potential regenerative treatments.
Solution
NurExone Biologic is developing ExoPTEN, an exosome-based drug delivery platform designed to address acute SCI by delivering therapeutic compounds directly to damaged neurons. The ExoTherapy platform leverages the natural ability of exosomes—nanosized extracellular vesicles—to cross the blood-brain barrier and target inflamed or damaged tissue. By loading exosomes with siRNA sequences or other active pharmaceutical ingredients (APIs), NurExone creates targeted nanodrugs with regenerative properties. This approach aims to promote neuronal regeneration and functional recovery following SCI.
Target Audience
The primary target audience includes patients with acute spinal cord injuries, as well as clinicians and researchers focused on developing regenerative therapies for neurological disorders.
Features
- Utilizes exosomes produced in-house via proprietary 2D and 3D bioreactor processes for high-quality, large-scale production.
- Employs a proprietary loading process to encapsulate therapeutic compounds, including siRNA sequences, within exosomes.
- Designed for non-invasive intranasal administration, facilitating easy access to the central nervous system.
- Targets the PTEN gene, a key regulator of neuronal growth and regeneration, using siRNA sequences.
- Granted Orphan Drug Designation by the FDA for ExoPTEN in the treatment of acute SCI.